Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (181-190 of 342) with videos related to

Pageof 35
Sort By:
Rheumatology (Oxford, England)|July 8, 2022
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARCLaura C Coates, Toby Garrood, Nicola Gullick, et al.
The Journal of Rheumatology|February 4, 2014
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11Laura C Coates, Oliver FitzGerald, Philip J Mease, et al.
The Lancet. Rheumatology|January 24, 2026
Trialblazers: patient-driven redesign of a clinical trial in psoriatic arthritisCaroline Struthers, Simon Hackett, Louise Hailey, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Nature Reviews. Rheumatology|November 11, 2016
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendationsLaure Gossec, Laura C Coates, Maarten de Wit, et al.
The Lancet. Rheumatology|August 1, 2024
Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritisDylan McGagh, Kaiyang Song, Hang Yuan, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
RMD Open|November 19, 2021
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritisEffie Pournara, Matthias Kormaksson, Peter Nash, et al.
Rheumatology and Therapy|December 15, 2025
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized TrialsDafna D Gladman, Lihi Eder, Carlo Selmi, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Pageof 35

Showing results (181-190 of 342) with videos related to

Sort By:
Pageof 35
Rheumatology (Oxford, England)|July 8, 2022
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARCLaura C Coates, Toby Garrood, Nicola Gullick, et al.
The Journal of Rheumatology|February 4, 2014
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11Laura C Coates, Oliver FitzGerald, Philip J Mease, et al.
The Lancet. Rheumatology|January 24, 2026
Trialblazers: patient-driven redesign of a clinical trial in psoriatic arthritisCaroline Struthers, Simon Hackett, Louise Hailey, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Nature Reviews. Rheumatology|November 11, 2016
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendationsLaure Gossec, Laura C Coates, Maarten de Wit, et al.
The Lancet. Rheumatology|August 1, 2024
Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritisDylan McGagh, Kaiyang Song, Hang Yuan, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
RMD Open|November 19, 2021
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritisEffie Pournara, Matthias Kormaksson, Peter Nash, et al.
Rheumatology and Therapy|December 15, 2025
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized TrialsDafna D Gladman, Lihi Eder, Carlo Selmi, et al.
The Journal of Rheumatology|December 1, 2025
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With GuselkumabWilliam Tillett, Laura C Coates, Marijn Vis, et al.
Pageof 35